Results 161 to 170 of about 4,513 (219)
Some of the next articles are maybe not open access.

Fosinopril: An overview

The American Journal of Cardiology, 1993
Angiotensin-converting enzyme (ACE) inhibitors are an effective, well-tolerated option for management of mild-to-moderate hypertension. An increase of nearly 250% in prescriptions between 1986 and 1990 testifies to the growing importance of this drug class.
openaire   +2 more sources

Fosinopril

Inpharma Weekly, 1992
Fosinopril, the first agent in a new chemical class of phosphorus-containing angiotensin-converting enzyme (ACE) inhibitors, has unique pharmacologic properties. Fosinopril administration leads to complete inhibition of plasma ACE activity for 12-24 h.
openaire   +3 more sources

Fosinopril Overdose in an Infant

Journal of Pharmacy Technology, 1999
Objective: To report an accidental fosinopril overdose in an infant. Case Summary: A 20-month-old African-American girl ingested approximately 16 mg/kg of fosinopril. Following aggressive gastric decontamination, the patient experienced an uneventful hospital course.
Kimberly A Stokes   +2 more
openaire   +1 more source

Fosinopril as a Possible Pemphigus-Inducing Drug

Dermatology, 2002
Fosinopril has recently been added to the angiotensin-converting enzyme inhibitors inducing pemphigus. The observation of a patient in whom pemphigus vulgaris (PV) worsened after taking fosinopril prompted us to study an experimental way to assess its responsibility.
PARODI, AURORA   +4 more
openaire   +3 more sources

Fosinopril

Drugs, 1996
Fosinopril is a phosphinic acid derivative which undergoes rapid hydrolysis after oral administration to the active diacid ACE inhibitor fosinoprilat. Cardiotropic effects have been associated with the drug, and the compensatory dual elimination route of fosinopril via renal and hepatic systems offers an opportunity for ACE inhibitor treatment of ...
A J, Wagstaff, R, Davis, D, McTavish
openaire   +2 more sources

Fosinopril: HIV-Associated Nephropathy (HIVAN)

Hospital Pharmacy, 2016
This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or
Joyce A, Generali, Dennis J, Cada
openaire   +2 more sources

Clinical Pharmacology of Fosinopril

Drug Investigation, 1991
Fosinopril is a novel phosphorus-containing angiotensin-converting enzyme (ACE) inhibitor which is distinguished from the majority of established ACE inhibitors by its beneficial effect on cardiac and renal haemodynamics in patients with essential hypertension and by a combination of pharmacokinetic properties — long plasma elimination half-life, dual ...
openaire   +1 more source

Fosinopril

Reactions Weekly, 2017
openaire   +2 more sources

Case Study: Fosinopril

2008
Fosinopril is an acyloxyalkyl ester of fosinoprilat, a phosphinic acid angiotensin-converting enzyme (ACE) inhibitor developed for the treatment of hypertension and congestive heart failure. The hydroxylphosphinylacetyl proline class of inhibitors exhibits high affinity for ACE and a high degree of efficacy for inhibition of the angiotensin I-induced ...
openaire   +1 more source

Fosinopril

Reactions Weekly, 2010
openaire   +1 more source

Home - About - Disclaimer - Privacy